Home Featured Page 243

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

PT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and...

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose...

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and...

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update

Filament Health Announces Q2 2021 Financial Results

PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of...

In Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience

Myth Busting: Magic Mushroom Spores Have Little to do with Potency

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.